PANACEABIO - Panacea Biotec
📢 Recent Corporate Announcements
Panacea Biotec's subsidiary, Panacea Biotec Pharma Limited, reported a fire incident at its Oncology Quality Control Laboratory in Baddi on April 30, 2026. The fire, caused by a short circuit, was quickly controlled, but operations at the facility are expected to be disrupted for approximately 5 to 7 days. Management has confirmed there were no casualties and that the facility is adequately insured. Importantly, the company does not anticipate a material impact on its overall financial performance due to this temporary halt.
- Fire incident occurred at the Baddi, Himachal Pradesh facility on April 30, 2026, due to a short circuit.
- Operations at the Oncology Facility are temporarily disrupted for an estimated period of 5 to 7 days.
- Zero human casualties or injuries were reported during the incident.
- Management states the disruption is not likely to have a material impact on the company's financials.
- The facility has adequate insurance coverage and the insurance company has been notified.
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding Assessment Year 2020-21. The ITAT set aside a previous order that had raised a tax demand of ₹9.16 Crore. This demand was originally based on a ₹3.44 Crore disallowance of expenses under Section 14A of the Income Tax Act. The ruling effectively cancels the entire demand, providing a positive financial impact for the company by removing this liability.
- ITAT set aside the CIT(A) order dated August 14, 2025, for Assessment Year 2020-21
- Cancellation of a tax demand amounting to ₹9.16 Crore
- Deletion of expense disallowance of ₹3.44 Crore previously added under Section 14A
- The ruling follows a Rectified Assessment Order originally passed on October 10, 2023
Panacea Biotec Limited has received a Letter of Award from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, for the supply of Diphtheria and Tetanus (Td) vaccines. The total value of the contract is INR 20.79 Crore. The supply is scheduled to be executed in multiple tranches starting from September/October 2026 and concluding by November/December 2028. This domestic order provides long-term revenue visibility for the company's vaccine segment.
- Total contract value aggregates to INR 20.79 Crore for Td Vaccine supply
- Order awarded by Central Medical Services Society (CMSS), a domestic government entity
- Execution timeline spans approximately two years from late 2026 to late 2028
- The contract involves Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP
Panacea Biotec has received four awards from the Industrial Tribunal, Mohali, regarding labor disputes dating back to 2014. The tribunal has ordered the reinstatement of terminated workers with 50% back wages and set aside the transfer of 23 workmen with full back wages. Additionally, the company has been directed to implement a wage revision for the affected workmen. While the company intends to challenge these orders in the High Court, the ruling introduces potential financial liabilities related to long-standing labor issues.
- Tribunal set aside the transfer of 23 workmen and granted relief of full back wages from the date of transfer.
- Ordered reinstatement of terminated workers with 50% back wages from the date of termination.
- Awarded a reasonable wage revision for workmen applicable for the period starting from 2014.
- Company plans to file appeals before the Hon’ble High Court of Punjab and Haryana against these awards.
- Management currently believes there will be no material adverse impact on financial or operational activities.
CA Rajesh Jain has tendered his resignation as a Non-Executive Independent Director of Panacea Biotec and its material subsidiary, Panacea Biotec Pharma Limited, effective June 30, 2026. The resignation is attributed to his increasing professional commitments and the evolving regulatory landscape, which prevent him from devoting sufficient time to the role. He currently holds directorships and committee chairmanships in other listed entities like Federal-Mogul Goetze and Sundrop Brands. The company has confirmed there are no other material reasons for his departure, and he will continue in his role until the effective date.
- Resignation of CA Rajesh Jain effective from the close of business hours on June 30, 2026.
- The director is also stepping down from the board of the material wholly owned subsidiary, Panacea Biotec Pharma Limited.
- Reason cited is inability to devote adequate time due to professional commitments and evolving regulatory requirements.
- The outgoing director holds significant positions in other listed firms, including chairmanship of the Audit Committee at Sundrop Brands Limited.
- A transition period of three months is provided as the resignation was tendered on March 30, 2026.
Panacea Biotec Limited has received an adverse ruling from the Commissioner of Income Tax (Appeals), New Delhi, which dismissed the company's appeals against penalty orders. These orders pertain to alleged under-reporting of income for the Assessment Years 2017-18, 2020-21, and 2021-22. The aggregate demand resulting from these penalties stands at approximately ₹9.38 crore. While the company intends to challenge this order before a higher appellate authority, the dismissal of the current appeal reinforces the immediate tax liability risk.
- CIT(A) dismissed three appeals against penalty orders issued by the Assistant Commissioner of Income Tax.
- The total aggregate tax demand involved in the litigation is approximately ₹9.38 crore.
- The penalties relate to alleged under-reporting of income for AY 2017-18, 2020-21, and 2021-22.
- Panacea Biotec plans to file a further appeal with the next appellate authority to contest the demand.
- Management currently maintains that the demand will not have a relevant impact on operations or financial activities.
Panacea Biotec Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the announcement of the audited financial results for the quarter and financial year ending March 31, 2026. The restriction applies to all designated persons and their immediate relatives. The window will remain closed until 48 hours after the financial results are officially disclosed to the stock exchanges.
- Trading window closure effective from April 1, 2026.
- Closure is related to the audited financial results for the quarter and year ending March 31, 2026.
- Restriction applies to all Designated Persons and their immediate relatives as per SEBI norms.
- Trading window will reopen 48 hours after the results are announced to the exchanges.
- The specific date for the Board meeting to approve results will be announced separately.
Panacea Biotec's wholly-owned subsidiary, Panacea Biotec Pharma Limited (PBPL), has received a favorable order from the Deputy Commissioner of State Tax, Maharashtra. The tax authority reduced a previous demand of ₹1.58 Crore to ₹0.81 Crore, which includes tax, interest, and penalties related to alleged ineligible Input Tax Credit from FY 2024-25. Despite the reduction, the company maintains that the remaining demand is not maintainable and plans to file a further appeal. The company has stated that this development will not have a material impact on its financial or operational activities.
- Tax demand reduced from ₹1.58 Crore to ₹0.81 Crore by Maharashtra tax authorities
- Litigation involves alleged excess or ineligible Input Tax Credit (ITC) and other tax liabilities
- Subsidiary PBPL intends to file an appeal against the revised ₹0.81 Crore order
- Management confirms no significant impact on financial, operation, or other activities
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding long-standing tax disputes for Assessment Years 2005-06 to 2012-13. The ITAT dismissed eight appeals by the tax department and allowed two appeals by the company, effectively quashing the previous assessment orders. This decision results in the cancellation of a massive tax demand totaling ₹329.49 Crore. The ruling removes a significant contingent liability and potential penalty exposure from the company's financial records.
- ITAT quashed assessment orders for eight Assessment Years spanning 2005-06 to 2012-13.
- Cancellation of a total tax demand amounting to ₹329.49 Crore previously raised by the Assessing Officer.
- Deletion of all expense disallowances that were under litigation since Financial Year 2015-16.
- The ruling dismisses eight appeals filed by the Deputy Commissioner of Income Tax (DCIT) against the company.
Panacea Biotec reported a consolidated net profit of ₹389 lakh for the quarter ended December 31, 2025, a slight decline from ₹444 lakh in the previous year. Consolidated revenue from operations grew marginally to ₹16,519 lakh compared to ₹16,349 lakh YoY. However, the standalone business faced significant pressure, reporting a net loss of ₹736 lakh against a profit of ₹965 lakh in the same period last year. The company continues to benefit from exceptional income, including a ₹858 lakh settlement with Apotex Inc. and deferred consideration from previous brand sales.
- Consolidated revenue from operations increased 1.04% YoY to ₹16,519 lakh.
- Formulations segment EBIT turned positive at ₹906 lakh compared to a loss of ₹758 lakh in Q3 FY25.
- Vaccines segment reported a loss of ₹257 lakh at the EBIT level for the quarter.
- Exceptional income of ₹1,679 lakh recognized in 9M FY26, including ₹858 lakh from a settlement with Apotex Inc.
- Standalone net loss for 9M FY26 widened significantly to ₹2,970 lakh from ₹284 lakh in 9M FY25.
Panacea Biotec reported a consolidated net profit of ₹3.89 crore for Q3 FY26, a slight decline from ₹4.44 crore in the same quarter last year. Consolidated revenue from operations grew marginally by 1% YoY to ₹165.19 crore. For the nine-month period, the company remains in a net loss of ₹6.16 crore, though this narrowed from a loss of ₹6.73 crore in the previous year. The results were significantly supported by an exceptional income of ₹16.79 crore in the 9M period, including a settlement with Apotex Inc.
- Consolidated Q3 revenue reached ₹165.19 crore, a marginal 1% increase over the previous year's ₹163.49 crore.
- Formulations segment profit improved significantly to ₹9.06 crore from a loss of ₹7.58 crore in Q3 FY25.
- Vaccines segment reported a loss of ₹2.57 crore for the quarter despite revenue of ₹99.24 crore.
- Exceptional income of ₹16.79 crore for 9M FY26 includes ₹8.58 crore from a settlement with Apotex Inc.
- Standalone net loss stood at ₹7.36 crore for Q3 FY26, compared to a profit of ₹9.65 crore in Q3 FY25.
Panacea Biotec Limited has filed its monthly update regarding the dematerialization of securities for January 2026 as per SEBI regulations. The company confirmed that no shares were dematerialized during the month. As of January 31, 2026, the total number of dematerialized shares remains at 6,11,01,526. The majority of these shares are held with NSDL, accounting for over 5.34 crore shares.
- Zero shares were dematerialized during the month of January 2026
- Total dematerialized shares as of January 31, 2026, stand at 6,11,01,526
- NSDL holds 5,34,32,223 dematerialized shares
- CDSL holds 76,69,303 dematerialized shares
Panacea Biotec's subsidiary facility in Baddi has received a 'Statement of non-compliance' with Good Manufacturing Practices (GMP) from Hungary's NCPHP, resulting in the revocation of its GMP certificates. The regulator has proposed halting supplies of non-vital products to the EU market, though no quality risks were found in products already released. The financial impact is expected to be minimal as the EU market contributed only 0.32% of the company's total consolidated net revenues in FY 2024-25. The company is currently implementing corrective and preventive actions (CAPA) to seek a re-inspection and restore compliance.
- NCPHP Hungary issued a Statement of non-compliance with GMP for the Baddi facility on February 03, 2026.
- All valid GMP certificates issued by NCPHP for the facility have been revoked following the inspection.
- Revenue from the European Union market accounted for only 0.32% of consolidated net revenues in FY 2024-25.
- No quality risks were observed by regulators for products already released into the market.
- Company is implementing CAPA and will request a re-inspection at the earliest to restore certificates.
Panacea Biotec has achieved a major milestone by completing the enrollment of 10,335 participants for the Phase III clinical trials of DengiAll, India's first indigenous single-shot dengue vaccine. The trial, conducted in collaboration with ICMR, will now move into a two-year monitoring phase to evaluate the vaccine's efficacy and immunogenicity. This development keeps the company on track for a projected market entry by 2027. Successful commercialization would address a significant unmet medical need in tropical regions, potentially creating a substantial long-term revenue stream.
- Completed enrollment of 10,335 study participants for Phase III clinical trials of DengiAll vaccine.
- DengiAll is positioned as India's first indigenous single-shot tetravalent dengue vaccine candidate.
- Two-year monitoring period initiated to examine long-term efficacy and immunogenicity post-administration.
- Commercial market launch is anticipated by 2027 following the completion of the observation period.
- Project is being executed in collaboration with the Indian Council of Medical Research (ICMR).
Panacea Biotec Limited has filed its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The document confirms that physical share certificates received for dematerialization were verified, cancelled, and the depository's name was updated in the records. This process was completed within the mandatory 15-day window as certified by the Registrar and Transfer Agent, Skyline Financial Services. Such filings are standard regulatory requirements for listed entities to ensure the integrity of the shareholding system.
- Quarterly compliance certificate for the period ending December 31, 2025
- Dematerialization of physical shares processed within the 15-day regulatory timeline
- Registrar Skyline Financial Services confirmed the mutilation and cancellation of physical certificates
- Securities involved are listed on both NSE and BSE
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 15% YoY to INR 624.8 Cr in FY21. The Vaccine segment grew 62% YoY to INR 227.8 Cr, while the Pharmaceutical segment declined 2% YoY to INR 397.0 Cr. In H1 FY26, Vaccine revenue reached INR 203.06 Cr (up 52% from INR 133.49 Cr) and Formulations reached INR 104.77 Cr (down 19% from INR 129.58 Cr).
Geographic Revenue Split
Export revenue from pharmaceutical products was INR 183.83 Cr (74% of pharma revenue), growing 11% YoY. Domestic pharmaceutical revenue was INR 65.42 Cr (26% of pharma revenue), which surged 92% YoY primarily due to increased contract manufacturing activities.
Profitability Margins
Gross and operating margins were impacted by segment shifts; the Pharmaceutical business earned an EBITDA of INR 69.0 Cr in FY21 (down from INR 90.9 Cr), while the Vaccine business turned around from an EBITDA loss of INR 13.7 Cr to a profit of INR 11.3 Cr.
EBITDA Margin
Consolidated EBITDA margin was 12.8% in FY21, representing a decline from 14.2% in FY20. This was driven by lower pharmaceutical sales during the pandemic and a shift in the product mix toward vaccines.
Capital Expenditure
Total assets were recorded at INR 1,178.8 Cr in FY21. Capital employed in the Vaccine segment was INR 870.9 Cr and INR 383.6 Cr in the Formulations segment as of September 2025.
Credit Rating & Borrowing
The company carries a CARE D (Single D) rating for bank facilities totaling INR 1,021.52 Cr. This rating reflects ongoing delays in servicing debt obligations due to a strained liquidity position.
Operational Drivers
Capacity Expansion
The company operates a pharmaceutical formulations facility at Baddi, Himachal Pradesh, and a vaccine/R&D center and herbal extraction facility at Lalru, Punjab. Specific MTPA or unit capacity figures were not disclosed.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
The company plans to launch 10-12 new products in the domestic market over the next 1-3 years. It aims to sustain leadership in the transplantation segment and regain market leadership in diabetology. Growth is also targeted through the 'Nurture & Grow' strategy for domestic formulations and expanding the reach of approved products in ICH and RoW markets.
Products & Services
Vaccines (including pediatric and adult), pharmaceutical formulations for transplantation and diabetology, and nutrition products including baby care items.
Brand Portfolio
Panacea Biotec, Panacea Biotec Pharma Limited (PBPL).
New Products/Services
Planned launch of 10-12 new products in the domestic market within 1-3 years to drive future revenue contribution.
Market Expansion
Targeting ICH (International Council for Harmonization) and Rest of World (RoW) markets for pharmaceutical formulations in a phased manner.
Market Share & Ranking
The company claims a leadership position in the Indian transplantation segment and is a leading research-based biotechnology company.
Strategic Alliances
The company transferred its pharma business to its 100% subsidiary, Panacea Biotec Pharma Limited (PBPL), to streamline operations and facilitate potential strategic investments.
External Factors
Industry Trends
The industry is shifting toward advanced biotechnology and specialized vaccines. Panacea is positioning itself by leveraging its established brand equity in vaccines and focusing on chronic therapeutic areas like diabetology which are growing in India.
Competitive Landscape
Competes with major Indian and global biotech and pharma firms in the vaccine and chronic therapy segments.
Competitive Moat
The moat is built on established brand equity in vaccines and proven technology development experience. This is sustainable due to high entry barriers in vaccine manufacturing, though it is currently threatened by liquidity constraints.
Macro Economic Sensitivity
Highly sensitive to healthcare spending and government vaccine procurement policies. The baby care market growth in India is a key macro driver for the nutrition business.
Consumer Behavior
Increasing demand for specialized baby care and nutrition products in India is driving a 25% growth in the consolidated nutrition business.
Geopolitical Risks
Exposure to international regulatory standards (ICH) and trade barriers in RoW markets could impact the 11% growth rate currently seen in exports.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent manufacturing standards and approvals from the International Council for Harmonization (ICH) for regulated markets.
Legal Contingencies
The company is involved in debt recovery proceedings, evidenced by a summons from the State Bank of India under the RBD Act, 1993, related to its significant outstanding debt of over INR 1,000 Cr.
Risk Analysis
Key Uncertainties
The primary uncertainty is the company's ability to restructure or service its INR 1,021.52 Cr debt, which is currently in default (CARE D). Failure to resolve this could lead to asset liquidation or operational halts.
Geographic Concentration Risk
74% of pharmaceutical revenue is concentrated in international export markets, making the company vulnerable to global trade and regulatory shifts.
Third Party Dependencies
Increased reliance on contract manufacturing for domestic revenue growth (which grew 92% YoY) introduces dependency on third-party production schedules.
Technology Obsolescence Risk
The biotechnology sector faces high risks of tech obsolescence; the company mitigates this through its dedicated R&D center and focus on new product launches.
Credit & Counterparty Risk
The company recorded an allowance for expected credit loss and doubtful advances of INR 4.15 Cr in H1 FY26, indicating some pressure on receivable quality.